UNITED THERAPEUTICS CORP

Insider trades reveal United Therapeutics CEO Martine Rothblatt buying and selling in a structured 10b‑5‑1 plan, signaling confidence and balanced risk for investors.

Edgémond James’ disciplined Rule 10b5‑1 trades show insider confidence: buying United Therapeutics stock at deep discounts and selling near market highs to manage risk while backing long‑term growth.

Explore how United Therapeutics’ CFO and CEO’s disciplined rule‑based trades on June 11 signal confidence, stable governance, and a solid growth outlook for the biotech firm.

United Therapeutics insider trades reveal CEO Martine Rothblatt’s confident long‑term bets amid strategic 10b5‑1 liquidity management – a signal for investors to watch.

Rothblatt’s 10b5‑1 buy and sell of United Therapeutics shares signals confidence and strategic exposure, offering investors insight into the stock’s value and future prospects.

USC CFO Edgemond James’s June 8 trades signal a planned liquidity move, converting options to cash while retaining a strong share stake in United Therapeutics.

CEO Martine Rothblatt’s June 8 buy of $146‑share United Therapeutics stocks signals long‑term confidence, offering investors a potential entry point amid a bullish pipeline and rising valuations.

Insider moves at United Therapeutics: CEO Martina Rothblatt’s bulk buys and sales reveal a disciplined option‑driven strategy, large trust holdings, and a possible short‑term supply spike that could hint at a valuation peak while underscoring long‑t…

Insider Paul Mahon’s disciplined 10 b5‑1 trades show a steady 49,400‑share holding, confirming long‑term confidence in United Therapeutics’ growth and pipeline.

U.S. CEO Martine Rothblatt’s disciplined 10‑b5‑1 plan buying 9,500 UTX shares at $146.03 shows confidence in United Therapeutics’ growth while keeping insider trades predictable and non‑volatility‑creating.